Drug General Information
Drug ID
D09EFC
Former ID
DCL000018
Drug Name
CAP-232
Drug Type
Small molecular drug
Indication Refractory renal cell carcinoma [ICD9: 189; ICD10:C64] Phase 2a [522404]
Pain; Solid tumours [ICD9: 338, 356.0, 356.8, 780, 140-199, 210-229; ICD10:G64, G90.0, R52, G89, C00-D48] Phase 2 [522404]
Therapeutic Class
Anticancer Agents
Structure
Download
2D MOL

3D MOL

Formula
C45H58N10O9S2
Canonical SMILES
CC(C(C(=O)N)NC(=O)C1CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)<br />N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5<br />=CC=CC=C5)N)O
InChI
1S/C45H58N10O9S2/c1-25(56)38(39(48)58)55-45(64)37-24-66-65-23-36(53-40(59)31(47)19-26-9-3-2-4-10-26)44(63)51-34(20-27-14-16-29(57)17-15-27)42(61)52-35(21-28-22-49-32-12-6-5-11-30(28)32)43(62)50-33(41(60)54-37)13-7-8-18-46/h2-6,9-12,14-17,22,25,31,33-38,49,56-57H,7-8,13,18-21,23-24,46-47H2,1H3,(H2,48,58)(H,50,62)(H,51,63)(H,52,61)(H,53,59)(H,54,60)(H,55,64)/t25-,31-,33+,34+,35-,36+,37+,38+/m1/s1
InChIKey
SNAJPQVDGYDQSW-DYCFWDQMSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Pyruvate kinase M2 Target Info Modulator [1572591]
References
Ref 522404ClinicalTrials.gov (NCT00735332) Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma. U.S. National Institutes of Health.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.